Skip to Main Content
Contribute Try STAT+ Today

A University of Chicago associate professor who worked as a clinical trial investigator for Five Prime Therapeutics was charged with insider trading in connection with study results for a key cancer drug.

In November 2020, Daniel Catenacci was a lead physician and investigator for a Phase 2 trial of a stomach cancer treatment when he learned of positive results from a Five Prime executive. The medicine, known as bemarituzumab, was widely tracked since stomach cancer is the third-leading cause of cancer deaths worldwide and prompted Amgen (AMGN) to buy the company for $1.9 billion a few months later.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment